All In Biotech

Drug Trial Radar · NCT07110883

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profiles, and Preliminary Efficacy of SYS6023 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 15, 2024

Primary completion

Oct 31, 2026

Study completion Oct 31, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • SYS6023Drug

    SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cyecle 1 (each cycle is 21 days).
  2. Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) (according to NCI-CTCAE 5.0)Time frame: Baseline up to 28 days post last dose,. Up to approximately 2 years.
  3. Recommended Phase 2 Dose(RP2D)Time frame: Up to approximately 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Tumor Hospital of Harbin

    Harbin, Heilongjiang, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.